TNFAIP8 variants as potential epidemiological and predictive biomarkers in ovarian cancer

Table 4 The association between TNFAIP8 polymorphisms and clinicopathological characteristics of ovarian cancer

Characteristics	rs11064				P*	rs1045241				P*	rs1045242				P*
Characteristics	AA	AG	GG	AG + GG	P*	CC	CT	TT	CC + CT	P*	AA	AG	GG	AG + GG	P*
FIGO stage					0.024					0.082					0.04
I/II	74	19	1	20	0.006	69	23	2	25	0.025	69	23	2	25	0.013
III/IV	71	43	2	45		68	44	4	48		66	44	6	50
Histologic grade					0.862					0.827					0.894
G1/G2	67	27	1	28	0.674	63	30	2	32	0.766	62	30	3	33	0.788
G3	78	35	2	37		74	37	4	41		73	37	5	42
Histological type					–					–					–
Serous	89	40	3	43	0.463	86	40	6	46	0.446	81	40	8	48	0.43
Mucinous	22	9	–	9		21	10	–	10		21	10	–	10
Endometrioid	21	11	–	11		18	14	–	14		18	14	–	14
Clear cell	13	2	–	2		12	3	–	3		12	3	–	3
Residual tumor					0.28					0.098					0.064
≤ 1 cm	86	44	2	46	0.112	79	49	4	53	0.033	77	49	6	55	0.019
> 1 cm	59	18	1	19		58	18	2	20		58	18	2	20
Ascites					–					0.739					0.508
≤ 100 ml	46	18	–	18	0.557	43	20	1	21	0.694	43	20	1	21	0.561
> 100 ml	99	44	3	47		94	47	5	52		92	47	7	54
Serum CA-125					0.800					0.573					0.69
≤ 35 U/m	32	12	1	13	0.736	31	12	2	14	0.562	31	12	2	14	0.467
> 35 U/ml	113	50	2	52		106	55	4	59		104	55	6	61
Recurrence					0.071					0.112					0.043
No	93	30	1	32	0.437	88	33	3	38	0.086	88	33	3	36	0.034
Yes	52	32	2	23		49	34	3	35		47	34	5	39

FIGO the Federation of Gynaecology and Obstetrics, G1 well differentiated, G2 moderately differentiated, G3 poorly differentiated
* Two-sided chi-squared test or Fisher’ s text

ISSN: 1475-2867